Pacific Biosciences Of California (PACB) Free Cash Flow Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Pacific Biosciences Of California | 481.66 Mn | 205.70 Mn | 12.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.22% |
| Dec 31, 2025 | -6.82% |
| Sep 30, 2025 | -0.30% |
| Jun 30, 2025 | -4.42% |
| Mar 31, 2025 | -21.10% |
| Dec 31, 2024 | -11.99% |
| Sep 30, 2024 | -19.82% |
| Jun 30, 2024 | -25.13% |
| Mar 31, 2024 | -24.53% |
| Dec 31, 2023 | -25.63% |
| Sep 30, 2023 | -35.84% |
| Jun 30, 2023 | -22.66% |
| Mar 31, 2023 | -38.78% |
| Dec 31, 2022 | -25.23% |
| Sep 30, 2022 | -26.09% |
| Jun 30, 2022 | -31.77% |
| Mar 31, 2022 | -33.71% |
| Dec 31, 2021 | -17.31% |
| Jun 30, 2021 | 4.44% |
| Mar 31, 2021 | -2.55% |
| Dec 31, 2020 | -55.19% |
| Sep 30, 2020 | -2.48% |
| Jun 30, 2020 | -23.33% |
| Mar 31, 2020 | 38.28% |
| Dec 31, 2019 | -2.96% |
| Sep 30, 2019 | -23.00% |
| Jun 30, 2019 | -5.23% |
| Mar 31, 2019 | -9.69% |
| Dec 31, 2018 | -5.35% |
| Sep 30, 2018 | -22.62% |
| Jun 30, 2018 | 1.02% |
| Mar 31, 2018 | -1.36% |
| Dec 31, 2017 | -2.64% |
| Sep 30, 2017 | -3.07% |
| Jun 30, 2017 | 7.59% |
| Mar 31, 2017 | -1.89% |
| Dec 31, 2016 | 0.83% |
| Sep 30, 2016 | 6.99% |
| Jun 30, 2016 | 9.12% |
| Mar 31, 2016 | 9.93% |
| Dec 31, 2015 | 47.59% |
| Sep 30, 2015 | 13.95% |